Compare COTY & TXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COTY | TXG |
|---|---|---|
| Founded | 1904 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 2012 | 2019 |
| Metric | COTY | TXG |
|---|---|---|
| Price | $2.12 | $17.41 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 17 | 14 |
| Target Price | $4.46 | ★ $17.18 |
| AVG Volume (30 Days) | ★ 6.2M | 2.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 76.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,892,900,000.00 | $245,893,000.00 |
| Revenue This Year | $0.12 | N/A |
| Revenue Next Year | $1.36 | $7.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 68.06 |
| 52 Week Low | $2.11 | $6.78 |
| 52 Week High | $5.79 | $23.56 |
| Indicator | COTY | TXG |
|---|---|---|
| Relative Strength Index (RSI) | 25.02 | 38.15 |
| Support Level | N/A | $11.62 |
| Resistance Level | $3.45 | $17.33 |
| Average True Range (ATR) | 0.09 | 1.34 |
| MACD | -0.01 | -0.50 |
| Stochastic Oscillator | 2.97 | 18.38 |
Coty is a global beauty maker that generates 65% of sales from prestige beauty products (primarily fragrances) and 35% from mass makeup, skin care, and fragrance. For the fragrance business, Coty licenses luxury and high-end brands including Gucci, Burberry, Hugo Boss, Davidoff, and Calvin Klein. In contrast, its consumer cosmetics business focuses on acquired mass brands such as CoverGirl, Max Factor, Rimmel, Sally Hansen, and Bourjois. It also collaborates with social media celebrity Kylie Jenner to manage makeup products bearing her name. By region, Coty generates close to 48% of sales from Europe, 40% from the Americas, and 12% from Asia-Pacific. German investment firm JAB is a controlling shareholder, with a 54% stake.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).